Compare LKFN & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | ODTX |
|---|---|---|
| Founded | 1872 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2009 | 2025 |
| Metric | LKFN | ODTX |
|---|---|---|
| Price | $58.10 | $20.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $66.50 | $35.75 |
| AVG Volume (30 Days) | 142.8K | ★ 245.6K |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $6.34 | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $26.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.36 | $15.10 |
| 52 Week High | $65.43 | $29.05 |
| Indicator | LKFN | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 48.10 |
| Support Level | $56.56 | $22.30 |
| Resistance Level | $62.23 | $28.53 |
| Average True Range (ATR) | 1.07 | 1.99 |
| MACD | -0.24 | -0.22 |
| Stochastic Oscillator | 0.19 | 50.43 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.